secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2026-09-03T20:03:58+00:00
Accession:  0001104659-26-105052
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone's etripamil approved in China by NMPA; first approval outside US
--------------------------------------------------------------------------

- NMPA approved etripamil nasal spray for PSVT in adults on Sept 3, 2026; first approval outside US.
- Approval triggers $2.0M milestone payment to Milestone; Everest Medicines to commercialize in Greater China.
- Milestone eligible for up to $98.0M in milestones and tiered royalties up to 18% on future sales.
- Based on Phase 3 RAPID and JX02002; JX02002 showed HR=3.002 (95% CI 1.578-5.711, p=0.0005) for conversion to sinus rhythm.
- No serious adverse events reported within 24 hours after dosing across Phase 3 studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465926105052/0001104659-26-105052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465926105052/tm2624766d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-105052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer